Invention Grant
- Patent Title: Activatable interleukin 12 polypeptides
-
Application No.: US16438166Application Date: 2019-06-11
-
Publication No.: US10696723B2Publication Date: 2020-06-30
- Inventor: William Winston , Daniel Hicklin , Vinay Bhaskar , Luke Evnin , Patrick Baeuerle , Jose Andres Salmeron Garcia , Heather Brodkin , Cynthia Seidel-Dugan
- Applicant: Werewolf Therapeutics, Inc.
- Applicant Address: US MA Cambridge
- Assignee: Werewolf Therapeutics, Inc.
- Current Assignee: Werewolf Therapeutics, Inc.
- Current Assignee Address: US MA Cambridge
- Agency: Hogan Lovells US LLP
- Main IPC: C07K14/54
- IPC: C07K14/54 ; C12N15/62 ; C12N15/63 ; C12N15/64 ; C07K16/28

Abstract:
The disclosure features fusion proteins that are conditionally active variants of IL-12. In one aspect, the full-length polypeptides of the invention have reduced or minimal cytokine-receptor activating activity even though they contain a functional cytokine polypeptide. Upon activation, e.g., by cleavage of a linker that joins a blocking moiety, e.g., a steric blocking polypeptide, in sequence to the active cytokine, the cytokine can bind its receptor and effect signaling.
Public/Granted literature
- US20190367576A1 ACTIVATABLE INTERLEUKIN 12 POLYPEPTIDES AND METHODS OF USE THEREOF Public/Granted day:2019-12-05
Information query